KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

Mostrar otras versiones (1)

BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited...

Descripción completa

Detalles Bibliográficos
Autores principales: van Grieken, N C T, Aoyma, T, Chambers, P A, Bottomley, D, Ward, L C, Inam, I, Buffart, T E, Das, K, Lim, T, Pang, B, Zhang, S L, Tan, I B, Carvalho, B, Heideman, D A M, Miyagi, Y, Kameda, Y, Arai, T, Meijer, G A, Tsuburaya, A, Tan, P, Yoshikawa, T, Grabsch, H I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629423/
https://www.ncbi.nlm.nih.gov/pubmed/23511561
http://dx.doi.org/10.1038/bjc.2013.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629423/
https://www.ncbi.nlm.nih.gov/pubmed/23511561
http://dx.doi.org/10.1038/bjc.2013.109

Ejemplares similares